ProSense™ system provides minimally invasive, in-office treatment for tumors, both benign and malignantץ IceCure sells its products in the US, among our U.S clients are breast centers in reputable institutions as well as private clinics operated by breast surgeons and radiologists. In other geographies, IceCure uses specialized distributors that provide clinical and technical sales support in Asia and Europe.
IceCure has FDA and CE approval for broad benign and malignant indications. The company is also in advanced regulatory process in China with the CFDA as well as other Asian and South American countries.
Thanks to its unique and innovative technology, IceCure participate in several clinical studies for treatment of lung cancer, Kidney cancer and breast cancer(1).
With the global trend of taking procedures from the operating room to the office environment and decreasing their costs, IceCure’s innovation brings the future to the present!
(1)Under clinical studies in the U.S and Japan